Elhami A, Mobed A, Soleimany R, Yazdani Y, Kazemi E, Mohammadi M
Anal Sci Adv. 2024; 5(9-10):e202400029.
PMID: 39479573
PMC: 11519542.
DOI: 10.1002/ansa.202400029.
Ish J, Chang C, Bookwalter D, Jones R, OBrien K, Kaufman J
Environ Health Perspect. 2024; 132(10):107701.
PMID: 39352804
PMC: 11444316.
DOI: 10.1289/EHP14729.
Bian J, Li H, Shang Y, Zhang F, Tang L
Int J Womens Health. 2024; 16:1541-1549.
PMID: 39319183
PMC: 11420331.
DOI: 10.2147/IJWH.S468624.
Lazzari G, Opattova A, Arena S
J Exp Clin Cancer Res. 2024; 43(1):146.
PMID: 38750579
PMC: 11094891.
DOI: 10.1186/s13046-024-03065-0.
Alam S, Giri P
Front Oncol. 2024; 14:1366223.
PMID: 38544837
PMC: 10966408.
DOI: 10.3389/fonc.2024.1366223.
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.
Tavares V, Marques I, de Melo I, Assis J, Pereira D, Medeiros R
Int J Mol Sci. 2024; 25(3).
PMID: 38339123
PMC: 10856127.
DOI: 10.3390/ijms25031845.
Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells.
Reavis H, Gysler S, McKenney G, Knarr M, Lusk H, Rawat P
JCI Insight. 2024; 9(5).
PMID: 38271085
PMC: 10972597.
DOI: 10.1172/jci.insight.170961.
Unveiling the potential anti-cancer activity of calycosin against multivarious cancers with molecular insights: A promising frontier in cancer research.
Sohel M, Zahra Shova F, Shuvo S, Mahjabin T, Mojnu Mia M, Halder D
Cancer Med. 2024; 13(3):e6924.
PMID: 38230908
PMC: 10905684.
DOI: 10.1002/cam4.6924.
The Role of Cancer Stem Cell Markers in Ovarian Cancer.
Fraszczak K, Barczynski B
Cancers (Basel). 2024; 16(1).
PMID: 38201468
PMC: 10778113.
DOI: 10.3390/cancers16010040.
The Impact of BRCA1 Expression on Survival Status in Ovarian Serous Carcinoma of Egyptian Patients.
Amin N, Ahmed B, Abou-Bakr A, Eissa S, Nassar H, Gad M
Asian Pac J Cancer Prev. 2023; 24(10):3613-3620.
PMID: 37898870
PMC: 10770685.
DOI: 10.31557/APJCP.2023.24.10.3613.
Trends in incidence and mortality for ovarian cancer in China from 1990 to 2019 and its forecasted levels in 30 years.
Feng J, Xu L, Chen Y, Lin R, Li H, He H
J Ovarian Res. 2023; 16(1):139.
PMID: 37452315
PMC: 10347789.
DOI: 10.1186/s13048-023-01233-y.
The Role of NQO1 in Ovarian Cancer.
Tossetta G, Fantone S, Goteri G, Giannubilo S, Ciavattini A, Marzioni D
Int J Mol Sci. 2023; 24(9).
PMID: 37175546
PMC: 10178676.
DOI: 10.3390/ijms24097839.
Alcohol intake and the risk of epithelial ovarian cancer.
LEsperance K, Grundy A, Abrahamowicz M, Arseneau J, Gilbert L, Gotlieb W
Cancer Causes Control. 2023; 34(6):533-541.
PMID: 36933150
DOI: 10.1007/s10552-023-01681-3.
The Role of Natural and Semi-Synthetic Compounds in Ovarian Cancer: Updates on Mechanisms of Action, Current Trends and Perspectives.
Islam M, Rahman M, Dhar P, Nowrin F, Sultana N, Akter M
Molecules. 2023; 28(5).
PMID: 36903316
PMC: 10004182.
DOI: 10.3390/molecules28052070.
Ovulation induction drug and ovarian cancer: an updated systematic review and meta-analysis.
Yu L, Sun J, Wang Q, Yu W, Wang A, Zhu S
J Ovarian Res. 2023; 16(1):22.
PMID: 36694251
PMC: 9872323.
DOI: 10.1186/s13048-022-01084-z.
PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers.
Alwosaibai K, Aalmri S, Mashhour M, Ghandorah S, Alshangiti A, Azam F
BMC Cancer. 2023; 23(1):13.
PMID: 36604635
PMC: 9814309.
DOI: 10.1186/s12885-022-10404-x.
Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy.
Ghose A, Bolina A, Mahajan I, Raza S, Clarke M, Pal A
Int J Environ Res Public Health. 2022; 19(19).
PMID: 36231355
PMC: 9565024.
DOI: 10.3390/ijerph191912057.
Ovarian neoplasia in adolescence: a retrospective chart review of girls with neoplastic ovarian tumors in Saudi Arabia.
AlDakhil L, Aljuhaimi A, Alkhattabi M, Alobaid S, Mattar R, Alobaid A
J Ovarian Res. 2022; 15(1):105.
PMID: 36114569
PMC: 9482250.
DOI: 10.1186/s13048-022-01033-w.
KLHL14: A Novel Prognostic Biomarker and Therapeutic Target for Ovarian Cancer.
Wang X, Sun R, Hong X, Chen C, Ding Y
J Oncol. 2022; 2022:9799346.
PMID: 36046368
PMC: 9423958.
DOI: 10.1155/2022/9799346.
Cost-effective Testing in Advanced Ovarian Cancer.
Kim M
Ann Lab Med. 2022; 43(1):3-4.
PMID: 36045051
PMC: 9467842.
DOI: 10.3343/alm.2023.43.1.3.